CAPR PE Ratio & Valuation,Is CAPR Overvalued

CAPR Relative Valuation

CAPR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CAPR is overvalued; if below, it's undervalued.

Historical Valuation

Capricor Therapeutics Inc (CAPR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 20.24 is considered Undervalued compared with the five-year average of -5.55. The fair price of Capricor Therapeutics Inc (CAPR) is between 35.41 to 61.38 according to relative valuation methord. Compared to the current price of 26.31 USD , Capricor Therapeutics Inc is Undervalued By 25.69%.

Relative Value

Fair Zone

35.41-61.38

Current Price：26.31

25.69%

Undervalued

-26.54

-22.11

EV/EBITDA

Capricor Therapeutics Inc. (CAPR) has a current EV/EBITDA of -22.11. The 5-year average EV/EBITDA is -5.38. The thresholds are as follows: Strongly Undervalued below -49.65, Undervalued between -49.65 and -27.52, Fairly Valued between 16.76 and -27.52, Overvalued between 16.76 and 38.90, and Strongly Overvalued above 38.90. The current Forward EV/EBITDA of -22.11 falls within the Historic Trend Line -Fairly Valued range.

-24.82

EV/EBIT

Capricor Therapeutics Inc. (CAPR) has a current EV/EBIT of -24.82. The 5-year average EV/EBIT is -4.05. The thresholds are as follows: Strongly Undervalued below -17.43, Undervalued between -17.43 and -10.74, Fairly Valued between 2.64 and -10.74, Overvalued between 2.64 and 9.33, and Strongly Overvalued above 9.33. The current Forward EV/EBIT of -24.82 falls within the Strongly Undervalued range.

20.24

Capricor Therapeutics Inc. (CAPR) has a current PS of 20.24. The 5-year average PS is 94.30. The thresholds are as follows: Strongly Undervalued below -253.78, Undervalued between -253.78 and -79.74, Fairly Valued between 268.35 and -79.74, Overvalued between 268.35 and 442.39, and Strongly Overvalued above 442.39. The current Forward PS of 20.24 falls within the Historic Trend Line -Fairly Valued range.

17.34

P/OCF

Capricor Therapeutics Inc. (CAPR) has a current P/OCF of 17.34. The 5-year average P/OCF is -0.62. The thresholds are as follows: Strongly Undervalued below -15.04, Undervalued between -15.04 and -7.83, Fairly Valued between 6.59 and -7.83, Overvalued between 6.59 and 13.80, and Strongly Overvalued above 13.80. The current Forward P/OCF of 17.34 falls within the Strongly Overvalued range.

-1064.84

P/FCF

Capricor Therapeutics Inc. (CAPR) has a current P/FCF of -1064.84. The 5-year average P/FCF is -28.29. The thresholds are as follows: Strongly Undervalued below -300.24, Undervalued between -300.24 and -164.26, Fairly Valued between 107.69 and -164.26, Overvalued between 107.69 and 243.66, and Strongly Overvalued above 243.66. The current Forward P/FCF of -1064.84 falls within the Strongly Undervalued range.

Capricor Therapeutics Inc (CAPR) has a current Price-to-Book (P/B) ratio of 15.43. Compared to its 3-year average P/B ratio of 9.43 , the current P/B ratio is approximately 63.59% higher. Relative to its 5-year average P/B ratio of 7.32, the current P/B ratio is about 110.69% higher. Capricor Therapeutics Inc (CAPR) has a Forward Free Cash Flow (FCF) yield of approximately -4.67%. Compared to its 3-year average FCF yield of -14.71%, the current FCF yield is approximately -68.26% lower. Relative to its 5-year average FCF yield of -11.63% , the current FCF yield is about -59.84% lower.

15.43

P/B

Median3y

9.43

Median5y

7.32

-4.67

FCF Yield

Median3y

-14.71

Median5y

-11.63

Competitors Valuation Multiple

The average P/S ratio for CAPR's competitors is 117.35, providing a benchmark for relative valuation. Capricor Therapeutics Inc Corp (CAPR) exhibits a P/S ratio of 20.24, which is -82.76% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of CAPR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of CAPR in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Capricor Therapeutics Inc (CAPR) currently overvalued or undervalued?

What is Capricor Therapeutics Inc (CAPR) fair value?

CAPR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Capricor Therapeutics Inc (CAPR) is between 35.41 to 61.38 according to relative valuation methord.

How does CAPR's valuation metrics compare to the industry average?

What is the current P/B ratio for Capricor Therapeutics Inc (CAPR) as of Jan 08 2026?

As of Jan 08 2026, Capricor Therapeutics Inc (CAPR) has a P/B ratio of 15.43. This indicates that the market values CAPR at 15.43 times its book value.

What is the current FCF Yield for Capricor Therapeutics Inc (CAPR) as of Jan 08 2026?

As of Jan 08 2026, Capricor Therapeutics Inc (CAPR) has a FCF Yield of -4.67%. This means that for every dollar of Capricor Therapeutics Inc’s market capitalization, the company generates -4.67 cents in free cash flow.

What is the current Forward P/E ratio for Capricor Therapeutics Inc (CAPR) as of Jan 08 2026?

As of Jan 08 2026, Capricor Therapeutics Inc (CAPR) has a Forward P/E ratio of -26.54. This means the market is willing to pay $-26.54 for every dollar of Capricor Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Capricor Therapeutics Inc (CAPR) as of Jan 08 2026?

As of Jan 08 2026, Capricor Therapeutics Inc (CAPR) has a Forward P/S ratio of 20.24. This means the market is valuing CAPR at $20.24 for every dollar of expected revenue over the next 12 months.

CAPR Valuation